Glycomimetics Stock News

GlycoMimetics (GLYC) has filed for a $250M mixed shelf offering.

GLYC earnings call for the period ending December 31, 2021.

GLYC earnings call for the period ending December 31, 2021.

GlycoMimetics press release (GLYC): Q4 GAAP EPS of -$0.33 beats by $0.01.Revenue of $0.18M (+12.5% Y/Y).

GlycoMimetics, Inc. (GLYC) CEO Harout Semerjian on Q4 2021 Results - Earnings Call Transcript

Companies Reporting Before The Bell • Travelzoo (NASDAQ: TZOO ) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban One (NASDAQ: UONEK ) is likely to report earnings for its fourth quarter. • Tile Shop Holdings (NASDAQ: TTSH ) is likely to report earnings for its fourth quarter. • Oxford Square Capital (NASDAQ: OXSQ ) is estimated to report quarterly earnings at $0.09 per share on revenue of $10.30 million. • Aurora Mobile (NASDAQ: JG ) is projected to report quarterly loss at $0.07 per share on revenue of $15.65 million. • Mobile TeleSystems (NYSE: MBT ) is estimated to report quarterly earnings at $0.19 per share on revenue of $1.69 billion. • LENSAR (NASDAQ: LNSR ) is estimated to report quarterly loss at $0.52 per share on revenue of $8.70 million. • Bluegreen Vacations (NYSE: BVH ) is likely to report quarterly earnings at $0.62 per share on revenue of $203.89 million. • Fulcrum Therapeutics (NASDAQ: FULC ) is projected to report quarterly loss at $0.

GlycoMimetics (NASDAQ:GLYC) is scheduled to announce Q4 earnings results on Thursday, March 3rd, before market open.The consensus EPS Estimate is -$0.34Over the last 3 months, EPS…

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its fourth quarter and 2021 year-end financial results on Thursday, March 3, 2022, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants and (216) 562-0466 for international participants, with participant code 4048456. Participants are encouraged to connect 15 minutes in advance of the call to ensure they

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its fourth quarter and 2021 year-end financial results on

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (the “Company”) (NASDAQ:GLYC) today announced that the compensation committee of the Company’s Board of Directors approved the grant on February 16, 2022 of a non-qualified stock option award to purchase an aggregate of 235,000 shares to Bruce Johnson, the Company’s new Senior Vice President and Chief Commercial Officer. The award was granted as an inducement equity award outside of the Company’s 2013 Equity Incentive Plan in accordance with

GlycoMimetics Inc. (NASDAQ:GLYC) price on Friday, February 11, rose 1.87% above its previous days close as an upside momentum from buyers pushed the stocks value to $1.09. A look at the stocks price movement, the close in the last trading session was $1.07, moving within a range at $1.06 and $1.15. The beta value (5-Year GlycoMimetics Inc. (NASDAQ: GLYC) Up 1.87%: This Is What Analysts Are Now Forecasting Read More »

NEW YORK , Feb. 8, 2022 /PRNewswire/ -- Sickle Cell Disease Treatment Market Facts at a Glance- Total Pages: 120 Companies: 10+ – Including Addmedica SAS, Bristol-Myers Squibb Co., Chiesi Pharmaceuticals BV, CRISPR Therapeutics AG, Emmaus Life Sciences Inc., Global Blood Therapeutics Inc., GlycoMimetics Inc., Medunik USA , Novartis AG, and Pfizer Inc. among others. Coverage: Key drivers, trends, and challenges; Product insights & news; Value chain analysis; Parent market analysis; Vendor landscape; COVID impact & recovery analysis Segments: Indication (sickle cell anemia and others) Geographies: APAC ( China and India ), Europe ( Germany and UK), North America (US), South America , and MEA Didn''t Find What You Were Looking For? Customize Report- Don''t miss out on the opportunity to speak to our analyst and know more insights about this market report. Our analysts can also help you customize this report according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

GlycoMimetics Inc (GLYC) shares closed today at 1.5% above its 52 week low of $1.37, giving the company a market cap of $71M. The stock is currently down 3.5% year-to-date, down 63.2% over the past 12 months, and down 78.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 3.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -3.4% The company's stock price performance over the past 12 months lags the peer average by 1004.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a clinical-stage biotechnology company, announced today that the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), and the Alliance for Clinical Trials in Oncology, have completed enrollment of 267 patients in the Phase 2 portion of the adaptive Phase 2/3 trial evaluating whether uproleselan improves overall survival in newly diagnosed patients 60 years or older with acute myeloid leukemia (AML)